@article{80046268-c325-4875-b57b-a802fe90b6bc,
  abstract     = {{<p>BACKGROUND: Chronic kidney disease (CKD) increases cardiovascular and mortality risk. Guidelines recommend statins for primary prevention in individuals aged ≥50 years with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2, but implementation and outcomes remain unclear. This study examined statin use and its association with all-cause mortality in individuals with CKD and no other indication for statin therapy.</p><p>METHODS: A retrospective cohort study was conducted using healthcare data derived from Region Halland, Sweden. Adults aged 50-89 years with ≥2 eGFR measurements &lt;60 mL/min/1.73 m2 during 2018-2021 were included, excluding those with prior cardiovascular disease, diabetes, primary hyperlipidemia, dialysis, or kidney transplantation. Follow-up from January 2021 to December 2023 included prevalence of statin use and all-cause mortality. Cox regression estimated adjusted hazard ratios (HR) for mortality, accounting for age, sex, CKD stage, albuminuria, hypertension, and use of statins, renin-angiotensin-aldosterone system (RAASi) inhibitors, and sodium-glucose-cotransporter-2 (SGLT2i) inhibitors.</p><p>RESULTS: Among 7,177 individuals (50% women), 38% received statins. Statin use was associated with lower three-year mortality (14% vs. 19%, p &lt; 0.001). Crude mortality rates were 42 vs. 57 deaths per 1,000 person-years. Statin use was associated with reduced mortality risk (HR 0.82, 95% CI:0.72-0.92). Higher age, advanced CKD stage, and hypertension were independently associated with increased mortality. RAASi use was protective (HR 0.31, 95% CI:0.27-0.35).</p><p>CONCLUSION: Statin therapy was associated with lower all-cause mortality but was underutilized in adults ≥50 years with CKD. These findings have supported broader implementation of guideline-recommended statin therapy.</p>}},
  author       = {{Malmquist, Julia and Davidge, Jason and Bjurström, Karl and Halling, Anders and Agvall, Björn}},
  issn         = {{0281-3432}},
  keywords     = {{Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Renal Insufficiency, Chronic/mortality; Aged; Middle Aged; Female; Male; Primary Prevention; Retrospective Studies; Aged, 80 and over; Glomerular Filtration Rate; Sweden/epidemiology; Cardiovascular Diseases/prevention & control; Proportional Hazards Models}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Informa Healthcare}},
  series       = {{Scandinavian Journal of Primary Health Care}},
  title        = {{Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications}},
  url          = {{http://dx.doi.org/10.1080/02813432.2026.2636586}},
  doi          = {{10.1080/02813432.2026.2636586}},
  volume       = {{44}},
  year         = {{2026}},
}

